- Home
- GAU vs CSTL Comparison
GAU vs CSTL Comparison
Compare GAU & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAU
- CSTL
- Stock Information
- Founded
- GAU 1999
- CSTL 2007
- Country
- GAU Canada
- CSTL United States
- Employees
- GAU N/A
- CSTL N/A
- Industry
- GAU
- CSTL Medical Specialities
- Sector
- GAU
- CSTL Health Care
- Exchange
- GAU Nasdaq
- CSTL Nasdaq
- Market Cap
- GAU 731.5M
- CSTL 661.7M
- IPO Year
- GAU N/A
- CSTL 2019
- Fundamental
- Price
- GAU $2.18
- CSTL $34.83
- Analyst Decision
- GAU Strong Buy
- CSTL Strong Buy
- Analyst Count
- GAU 2
- CSTL 6
- Target Price
- GAU $3.00
- CSTL $38.67
- AVG Volume (30 Days)
- GAU 2.7M
- CSTL 468.7K
- Earning Date
- GAU 11-06-2025
- CSTL 11-03-2025
- Dividend Yield
- GAU N/A
- CSTL N/A
- EPS Growth
- GAU N/A
- CSTL N/A
- EPS
- GAU N/A
- CSTL N/A
- Revenue
- GAU $352,642,000.00
- CSTL $343,530,000.00
- Revenue This Year
- GAU $84.10
- CSTL N/A
- Revenue Next Year
- GAU $50.80
- CSTL N/A
- P/E Ratio
- GAU N/A
- CSTL N/A
- Revenue Growth
- GAU 111.43
- CSTL 10.15
- 52 Week Low
- GAU $1.00
- CSTL $14.59
- 52 Week High
- GAU $3.12
- CSTL $35.49
- Technical
- Relative Strength Index (RSI)
- GAU 41.74
- CSTL 74.82
- Support Level
- GAU $2.12
- CSTL $32.96
- Resistance Level
- GAU $2.25
- CSTL $35.49
- Average True Range (ATR)
- GAU 0.14
- CSTL 1.81
- MACD
- GAU -0.02
- CSTL 0.17
- Stochastic Oscillator
- GAU 41.39
- CSTL 93.75
About GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.